{
  "title": "3650s1a",
  "outline": [
    {
      "level": "H1",
      "text": "October 20, 2000  -  Joint Meeting of the",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Nonprescription Drugs & Gastrointestinal Advisory Committees",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Prilosec 1(omeprazole magnesium, Astra Zeneca & Procter & Gamble, NDA 21-229)",
      "page": 1
    },
    {
      "level": "H2",
      "text": "Currently, there are two classes of drugs, antacids and acid reducers (histamine-2 receptor antagonists),",
      "page": 1
    },
    {
      "level": "H2",
      "text": "available in the OTC market to treat heartburn.  Both antacids and acid reducers are indicated for the treatment",
      "page": 1
    },
    {
      "level": "H2",
      "text": "of acute occasional heartburn symptoms. The acid reducers have an additional claim for the prevention of meal",
      "page": 1
    },
    {
      "level": "H2",
      "text": "induced heartburn symptoms if ingested at specified times prior to a meal. At today’s meeting, the sponsor is",
      "page": 1
    },
    {
      "level": "H2",
      "text": "seeking the approval of omeprazole in the OTC setting for these indications and for the additional indication of",
      "page": 1
    },
    {
      "level": "H2",
      "text": "24-hour prevention of heartburn.  Omeprazole, a proton-pump inhibitor, is currently indicated Rx for the",
      "page": 1
    },
    {
      "level": "H2",
      "text": "treatment of duodenal and gastric ulcer, symptomatic Gastroesophageal Reflux Disease (GERD), erosive",
      "page": 1
    },
    {
      "level": "H2",
      "text": "esophagitis, and pathological hypersecretory conditions.  In support of the proposed OTC marketing, the",
      "page": 1
    },
    {
      "level": "H2",
      "text": "sponsor conducted studies to evaluate the efficacy of omeprazole 10 mg and 20 mg for the treatment of acute",
      "page": 1
    },
    {
      "level": "H2",
      "text": "symptomatic heartburn (studies 092, 095, 017, 018, 019), for the prevention of meal induced heartburn (studies",
      "page": 1
    },
    {
      "level": "H2",
      "text": "005 and 006) and for the 24 hour prevention of heartburn (studies 171 and 183).  They also conducted five",
      "page": 1
    },
    {
      "level": "H2",
      "text": "actual use studies (studies 003, 067, 014, 022 and 091) to evaluate consumer usage patterns and dosing",
      "page": 1
    },
    {
      "level": "H2",
      "text": "compliance.",
      "page": 1
    },
    {
      "level": "H3",
      "text": "A. In studies 092 and 095, the primary endpoint for efficacy was the occurrence of sustained complete relief of",
      "page": 1
    },
    {
      "level": "H2",
      "text": "the first treated episode of heartburn.  Based on the primary measure of efficacy, is there a clinically",
      "page": 1
    },
    {
      "level": "H2",
      "text": "significant improvement of acute symptomatic heartburn in either the 10 or 20-mg omeprazole groups",
      "page": 1
    },
    {
      "level": "H2",
      "text": "compared to placebo? Please explain your answer.",
      "page": 1
    },
    {
      "level": "H3",
      "text": "B. In studies 005 and 006, the primary endpoint for efficacy was the percentage of subjects heartburn-free over",
      "page": 1
    },
    {
      "level": "H2",
      "text": "the entire four-hour period after a provocative meal.",
      "page": 1
    },
    {
      "level": "H3",
      "text": "1. Based on the primary measure of efficacy, is there a clinically significant improvement of heartburn",
      "page": 1
    },
    {
      "level": "H2",
      "text": "symptoms in either the 10 or 20 mg omeprazole groups compared to placebo?  Please explain your",
      "page": 1
    },
    {
      "level": "H2",
      "text": "answer.",
      "page": 1
    },
    {
      "level": "H3",
      "text": "2. Are the analyses of the pre-specified secondary endpoints supportive of the primary study outcome?",
      "page": 1
    },
    {
      "level": "H2",
      "text": "Do they add information regarding clinically significant treatment effect?",
      "page": 1
    },
    {
      "level": "H3",
      "text": "C. In studies 171 and 183, the primary endpoint for efficacy was the complete prevention of heartburn between",
      "page": 1
    },
    {
      "level": "H2",
      "text": "the first two doses of therapy.",
      "page": 1
    },
    {
      "level": "H3",
      "text": "1. Based on the primary measure of efficacy, is there a clinically significant improvement of heartburn",
      "page": 1
    },
    {
      "level": "H2",
      "text": "symptoms in either the 10 or 20 mg omeprazole groups compared to placebo?  Please explain your",
      "page": 1
    },
    {
      "level": "H2",
      "text": "answer.",
      "page": 1
    },
    {
      "level": "H3",
      "text": "2. Are the analyses of the pre-specified secondary endpoints supportive of the primary study outcome?",
      "page": 1
    },
    {
      "level": "H2",
      "text": "Do they add information regarding clinically significant treatment effect?",
      "page": 1
    },
    {
      "level": "H3",
      "text": "D. Based on the types and frequency of adverse events reported in the clinical trials and in the post-marketing",
      "page": 1
    },
    {
      "level": "H2",
      "text": "adverse events database, are the safety concerns for the OTC marketing of omeprazole able to be",
      "page": 1
    },
    {
      "level": "H2",
      "text": "addressed solely by labeling (identifying risks) to consumers for (a) short term or (b) chronic intermittent",
      "page": 1
    },
    {
      "level": "H2",
      "text": "use? In answering this question, please consider the reports of anaphylaxis/angioedema/urticaria, liver",
      "page": 1
    },
    {
      "level": "H2",
      "text": "toxicity, white blood cell disorders and severe skin reactions.",
      "page": 1
    },
    {
      "level": "H3",
      "text": "E. Do other safety concerns affect acceptability of the OTC marketing of omeprazole? In answering this",
      "page": 1
    },
    {
      "level": "H2",
      "text": "question, please consider the questions raised by the FDA reviewer regarding: 1) the masking of serious",
      "page": 1
    },
    {
      "level": "H2",
      "text": "disease; 2) the potential for genotoxicity, tumorigenicity,  and fetal and developmental toxicity; 3) rebound",
      "page": 1
    },
    {
      "level": "H2",
      "text": "hyperacidity reported in the literature with discontinuation of therapy; and 4) hypergastrinemia that may be",
      "page": 1
    },
    {
      "level": "H2",
      "text": "associated with the chronic or chronic intermittent use of omeprazole.",
      "page": 1
    },
    {
      "level": "H3",
      "text": "F. Are there drug-drug interactions that affect acceptability of OTC marketing of omeprazole?",
      "page": 2
    },
    {
      "level": "H3",
      "text": "G. In the actual use studies, approximately 65% of the subset of subjects using the product only for the",
      "page": 2
    },
    {
      "level": "H2",
      "text": "prevention of heartburn exceeded the 10 consecutive day limit for dosing recommended on the label.",
      "page": 2
    },
    {
      "level": "H2",
      "text": "(Note: 19% to 22% of consumers using omeprazole for both acute symptoms and prevention similarly",
      "page": 2
    },
    {
      "level": "H3",
      "text": "exceeded the 10 consecutive day limit for dosing recommended on the label).  Do these results suggest that",
      "page": 2
    },
    {
      "level": "H2",
      "text": "omeprazole will likely be used by consumers on a chronic basis for conditions other than episodic heartburn",
      "page": 2
    },
    {
      "level": "H2",
      "text": "(e.g. GERD)?   Is the treatment of GERD an acceptable OTC indication?",
      "page": 2
    },
    {
      "level": "H3",
      "text": "H. Based on the results of the actual use and label comprehension studies, has the sponsor presented",
      "page": 2
    },
    {
      "level": "H2",
      "text": "adequate data to substantiate that consumers will be able to use omeprazole appropriately in the OTC",
      "page": 2
    },
    {
      "level": "H2",
      "text": "setting for: 1) acute symptomatic treatment; 2) prevention for up to 10 days.",
      "page": 2
    },
    {
      "level": "H2",
      "text": "In responding, consider these factors:",
      "page": 2
    },
    {
      "level": "H2",
      "text": "a) The ability of consumers to appropriately self-select.",
      "page": 2
    },
    {
      "level": "H2",
      "text": "b) The ability of consumers to use the correct dosage and for the period of time specified in the label.",
      "page": 2
    },
    {
      "level": "H2",
      "text": "c) The ability of consumers to identify when they should see a physician before using the product and",
      "page": 2
    },
    {
      "level": "H2",
      "text": "d) The ability of consumers to identify serious adverse events.",
      "page": 2
    },
    {
      "level": "H2",
      "text": "e) The ability of consumers to avoid interacting drugs.",
      "page": 2
    },
    {
      "level": "H2",
      "text": "Has the sponsor provided sufficient evidence to support the approval of omeprazole 10 mg and/or 20 mg for",
      "page": 2
    },
    {
      "level": "H2",
      "text": "use in the OTC setting for:",
      "page": 2
    },
    {
      "level": "H3",
      "text": "1. Acute symptomatic heartburn?  Please explain.",
      "page": 2
    },
    {
      "level": "H3",
      "text": "2. Prevention of episodic or chronic heartburn? Please explain.",
      "page": 2
    },
    {
      "level": "H2",
      "text": "a) If yes to either, are there any additional studies or risk management programs needed post-",
      "page": 2
    },
    {
      "level": "H2",
      "text": "b) If no, what additional studies or risk management programs are necessary to support approval for",
      "page": 2
    },
    {
      "level": "H3",
      "text": "J. If the Committee recommends approval of omeprazole for use in the OTC setting, please discuss any",
      "page": 2
    },
    {
      "level": "H2",
      "text": "recommendations regarding information to be conveyed in labeling (e.g., to help consumers select between",
      "page": 2
    },
    {
      "level": "H2",
      "text": "omeprazole and other currently available OTC products, and to help consumers use omeprazole safely and",
      "page": 2
    },
    {
      "level": "H2",
      "text": "effectively).",
      "page": 2
    }
  ]
}